[Treatment of acute promyelocytic leukemia--combined use of all-trans retinoic acid and granulocyte colony-stimulating factor]. 1995

H Tsurumi, and T Yamada, and M Sawada, and N Nakamura, and T Takahashi, and H Moriwaki, and Y Muto
First Department of Internal Medicine, Gifu University School of Medicine.

We evaluated the effect of treatment by all-trans retinoic acid (ATRA) in 9 patients with acute promyelocytic leukemia (APL). Of 6 patients who had circulating leukemic blasts before treatment, 3 initially received ATRA alone but died of respiratory failure due to retinoic acid syndrome (RAS). High dose steroid therapy did not rescue RAS in these patients. Another 3 who were given intensive chemotherapy followed by ATRA and/or granulocyte colony-stimulating factor (G-CSF) achieved complete remission (CR). Of 3 patients without peripheral leukemic blasts before treatment, 1 received intensive chemotherapy followed by G-CSF and reached CR, 1 who had been previously given ATRA did not respond to ATRA, and 1 did not initially respond sufficiently to ATRA alone but responded dramatically to ATRA plus G-CSF. In the treatment of APL, appropriate combination of ATRA, G-CSF and chemotherapy should always be taken into consideration. In addition, RAS have to be carefully avoided when applying ATRA therapy in patients who have circulating leukemic blasts before treatment.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014212 Tretinoin An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE). Retinoic Acid,Vitamin A Acid,Retin-A,Tretinoin Potassium Salt,Tretinoin Sodium Salt,Tretinoin Zinc Salt,Vesanoid,all-trans-Retinoic Acid,beta-all-trans-Retinoic Acid,trans-Retinoic Acid,Acid, Retinoic,Acid, Vitamin A,Acid, all-trans-Retinoic,Acid, beta-all-trans-Retinoic,Acid, trans-Retinoic,Potassium Salt, Tretinoin,Retin A,Salt, Tretinoin Potassium,Salt, Tretinoin Sodium,Salt, Tretinoin Zinc,Sodium Salt, Tretinoin,Zinc Salt, Tretinoin,all trans Retinoic Acid,beta all trans Retinoic Acid,trans Retinoic Acid
D015473 Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION. Leukemia, Myeloid, Acute, M3,Leukemia, Progranulocytic,Myeloid Leukemia, Acute, M3,Progranulocytic Leukemia,Promyelocytic Leukemia, Acute,AML M3,Acute Promyelocytic Leukemia,Leukemia, Acute Promyelocytic,M3 ANLL,ANLL, M3,Acute Promyelocytic Leukemias

Related Publications

H Tsurumi, and T Yamada, and M Sawada, and N Nakamura, and T Takahashi, and H Moriwaki, and Y Muto
August 1993, Internal medicine (Tokyo, Japan),
H Tsurumi, and T Yamada, and M Sawada, and N Nakamura, and T Takahashi, and H Moriwaki, and Y Muto
October 1996, International journal of hematology,
H Tsurumi, and T Yamada, and M Sawada, and N Nakamura, and T Takahashi, and H Moriwaki, and Y Muto
January 2015, Cancer cell international,
H Tsurumi, and T Yamada, and M Sawada, and N Nakamura, and T Takahashi, and H Moriwaki, and Y Muto
July 1999, Blood,
H Tsurumi, and T Yamada, and M Sawada, and N Nakamura, and T Takahashi, and H Moriwaki, and Y Muto
May 2004, Leukemia research,
H Tsurumi, and T Yamada, and M Sawada, and N Nakamura, and T Takahashi, and H Moriwaki, and Y Muto
December 1999, Chinese medical journal,
H Tsurumi, and T Yamada, and M Sawada, and N Nakamura, and T Takahashi, and H Moriwaki, and Y Muto
November 1994, [Rinsho ketsueki] The Japanese journal of clinical hematology,
H Tsurumi, and T Yamada, and M Sawada, and N Nakamura, and T Takahashi, and H Moriwaki, and Y Muto
November 1989, Japanese journal of cancer research : Gann,
H Tsurumi, and T Yamada, and M Sawada, and N Nakamura, and T Takahashi, and H Moriwaki, and Y Muto
August 1997, International journal of hematology,
H Tsurumi, and T Yamada, and M Sawada, and N Nakamura, and T Takahashi, and H Moriwaki, and Y Muto
March 1988, Zhonghua yi xue za zhi,
Copied contents to your clipboard!